Vyxeos versus 7 + 3 for Older Patients with High-Risk AML - 102194

Spotlight
Video

Vyxeos versus 7 + 3 for Older Patients with High-Risk AML

moffitt has 4 videos Subscribe Here

Loading........
Description: Jeffrey E. Lancet, MD of Moffitt Cancer Center gives an overview of a phase 3 randomized trial, which focused on the use of vyxeos (CPX-351) compared to cytarabine and daunorubicin (7+3) in older patients with therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
Shared By : moffitt
Posted on : 08/11/17
Added : 1 year ago